# Safety, Tolerability, PK, Dosimetry, MTD and Preliminary Efficacy of Intra-lesionally Injected AvidinOX, Followed by IV Escalating Doses of [177Lu]DOTA-biotin in Pts With Injectable Solid Tumors or Lymphomas

> **NCT03188328** · PHASE1 · TERMINATED · sponsor: **Alfasigma S.p.A.** · enrollment: 3 (actual)

## Conditions studied

- Inoperable Solid Tumors or Lymphomas

## Interventions

- **DRUG:** AvidinOX
- **DRUG:** 177Lu-ST2210
- **DRUG:** 177Lu-ST2210

## Key facts

- **NCT ID:** NCT03188328
- **Lead sponsor:** Alfasigma S.p.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-08-07
- **Primary completion:** 2019-06-30
- **Final completion:** 2019-07-01
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** low recruitment rate
- **Last updated:** 2019-07-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03188328

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03188328, "Safety, Tolerability, PK, Dosimetry, MTD and Preliminary Efficacy of Intra-lesionally Injected AvidinOX, Followed by IV Escalating Doses of [177Lu]DOTA-biotin in Pts With Injectable Solid Tumors or Lymphomas". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03188328. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*